New England Journal of Medicine· 2014Q1

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke et al.

1,510citations
Q1SCImago
2014year

Short summary

Obinutuzumab combined with chlorambucil significantly improved progression-free survival (26.7 months vs. 11.1 months) and overall survival in patients with chronic lymphocytic leukemia (CLL) and coexisting conditions, outperforming rituximab-chlorambucil.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine